The genitourinary tumour drug developer's latest round follows a June series C-plus round featuring C&D, Tigermed and SAIC Capital.

Asieris Pharmaceuticals, a China-based oncology therapy developer backed by corporates C&D, SAIC and Tigermed, has completed a RMB700m ($106m) series D round led by venture capital firm Qiming Venture Partners, DealStreetAsia reported today.

Founded in 2010, Asieris is working on therapeutics for genitourinary tumours and its lead drug candidate, APL-1202, is currently in phase 3 clinical trials.

The round followed approximately $59m in series C-plus funding in June this year from medical researcher Tigermed, supply chain services firm C&D and…

Subscribe to go deeper

GCV subscribers get access to all our proprietary data and deep-dive articles, as well as the global directory of CVC investors.



Not sure if you have a subscription?
Robert Lavine

Robert Lavine is special features editor for Global Venturing.
Email LinkedIn